Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.

J A Rock, John A. Rock, J A Truglia, Richard Caplan, R J Caplan
Obstetrics and gynecology · 1993 · vol. 82(2) , pp. 198–205 · PMID:8336864 · W22588564
article OA: closed CC0 ⤵ 55 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This randomized study found Zoladex and danazol equally effective and well-tolerated for treating endometriosis, with Zoladex causing greater estradiol suppression and danazol more androgenic side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study. METHODS: Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks. Efficacy was assessed by determination of pelvic signs and symptoms scores and revised AFS endometriosis scores. Endocrine effects were determined by measurements of hormone levels. Safety was evaluated by physical examination, laboratory indices, occurrence of adverse events, and bone mineral density changes. RESULTS: Both treatments significantly (P < .0001) reduced mean subjective signs and symptoms scores both during and after therapy. The mean percent reduction in the revised AFS endometriosis score after 24 weeks of treatment was 53% for Zoladex and 33% for danazol, and reduction in the endometrial implants score was 56% for Zoladex and 46% for danazol. Serum estradiol levels decreased to the postmenopausal range in the Zoladex group and to the early follicular phase range in the danazol group. Hypoestrogenic effects occurred more frequently with Zoladex, whereas androgenic side effects were more common with danazol. There was a higher percentage of withdrawals due to adverse events with danazol than with Zoladex. Mean bone mineral density decreased from baseline by 5.4% in the Zoladex group and increased by 1.0% in the danazol group at the end of treatment. CONCLUSION: Zoladex is as well tolerated and as effective as danazol in the treatment of premenopausal women with endometriosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Danazol Endometriosis Goserelin Pelvic Neoplasms Administration, Oral Adult Danazol Danazol Danazol Drug Implants Endometriosis Estradiol Estradiol Female Goserelin Goserelin Goserelin Humans Pelvic Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (39)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:34.315996+00:00
License: CC0 · commercial use OK